PTC Therapeutics (FRA:BH3) Current Accrued Expense : €183.5 Mil (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is PTC Therapeutics Current Accrued Expense?

PTC Therapeutics's Current Accrued Expense for the quarter that ended in Mar. 2024 was €183.5 Mil.

PTC Therapeutics's quarterly Current Accrued Expense increased from Sep. 2023 (€192.8 Mil) to Dec. 2023 (€225.7 Mil) but then declined from Dec. 2023 (€225.7 Mil) to Mar. 2024 (€183.5 Mil).

PTC Therapeutics's annual Current Accrued Expense increased from Dec. 2021 (€130.2 Mil) to Dec. 2022 (€152.9 Mil) and increased from Dec. 2022 (€152.9 Mil) to Dec. 2023 (€225.7 Mil).

PTC Therapeutics Current Accrued Expense Historical Data

The historical data trend for PTC Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PTC Therapeutics Current Accrued Expense Chart

PTC Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

64.34

91.71

130.16

152.86

225.69

PTC Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial															152.24	185.51	192.81	225.69	183.54

PTC Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

PTC Therapeutics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of PTC Therapeutics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

PTC Therapeutics (FRA:BH3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PTC Therapeutics Inc (FRA:BH3) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

PTCT:USA BH3:Germany

Address

100 Corporate Court, South Plainfield, NJ, USA, 07080

Website

https://www.ptcbio.com

PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.

PTC Therapeutics (FRA:BH3) Headlines

No Headlines